Form 4: CRISPR Therapeutics Director Granted 13,000 Stock Options

CRISPR Therapeutics AG Director Ali Behbahani was granted 13,000 stock options with an exercise price of $38.57, aligning his interests with the company's long-term performance.

Summary

• Ali Behbahani, a Director of CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options.
• The stock options have an exercise price of $38.57 per common share.
• The grant date for these options was June 5, 2025.
• The options will vest in 12 equal monthly installments, commencing on June 30, 2025.
• The final installment will vest on the earlier of the one-year anniversary of the grant date (June 5, 2026) or the date of the 2026 Annual General Meeting of Shareholders.
• The stock options are set to expire on June 5, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably, though it is a routine compensation disclosure.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued commitment and performance from the director over a one-year period.

Future Outlook

The vesting schedule of the granted stock options indicates a future alignment of the director's financial interests with the company's performance over the next year, with the options exercisable for a decade.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like CRISPR Therapeutics, to attract, retain, and incentivize key personnel by linking their compensation to the company's stock performance and long-term success.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a standard practice across publicly traded companies, particularly in high-growth sectors like biotechnology.
• The specific number of options (13,000) and the exercise price ($38.57) are specific to CRISPR Therapeutics' compensation structure and market valuation at the time of grant, and would require a detailed peer group analysis to assess against industry benchmarks for director compensation packages.

Related Party Transactions

• The grant of stock options to Ali Behbahani, a Director of CRISPR Therapeutics AG, constitutes a transaction with a related party, which is a standard component of executive and director compensation packages.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacted, such compensation practices can set precedents for broader equity incentive programs within the company.

Next Steps

• The options will begin vesting in monthly installments starting June 30, 2025.
• The director will acquire beneficial ownership of common shares as the options vest over the next year.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Vesting